Study	Reason for exclusion
Bar‐Or 2007	RCT comparing atorvastatin add to BHT‐3009 with BHT‐3009, a DNA vaccine that it is not currently approved for MS, did not meet our protocol criteria.
Laplaud 2008	An abstract reported in the 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. No useful outcome data for analysis.
Paul 2008	Open‐label baseline‐to‐treatment trial to assess high dose of atorvastatin in relapsing‐remitting MS without a control group.
Rudick 2009	A retrospective analysis of 40 MS patients treated with five different statins.
Sena 2003	Case series study of 7 relapsing‐remitting MS patients treated with 40 mg lovastatin.
Vollmer 2004	Case series study of 30 relapsing‐remitting MS patients treated with 80 mg simvastatin.
Wang 2008	Co‐intervention was not imbalanced between treatment groups, the authors enrolled MS patients only in acute exacerbation stage.

RCT:randomised controlled trial